Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union

Approval follows a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) EC approval marks a significant milestone for people living with this ultra-rare primary immunodeficiency and was granted under exceptional circumstances Norgine to lead...